The Guardian has analyzed “hundreds of food aid contracts awarded by the U.S. Department of Agriculture (USDA) in 2010-11 to show where the money goes,” the newspaper reports. “Two-thirds of food for the billion-dollar U.S. food aid program last year was bought from just three U.S.-based multinationals,” ADM, Cargill, and Bunge, the newspaper notes, adding that “these three agribusinesses sold the U.S. government 1.2 million tons of food, or almost 70 percent of the total bought” (Provost/Lawrence, 7/18). In a separate article, the Guardian writes, “Food aid has also become a valuable business for a variety of smaller food companies,” as well as shipping firms and non-governmental organizations (Provost, 7/19). In an interactive feature, the Guardian “[e]xplore[s] which companies sold food aid products to the government last year, what was bought, and where it was sent” (Provost/Hughes, 7/20). And another article describes how the newspaper analyzed the data (Hughes, 7/19).
Private Sector Involvement
In a feature analysis, Devex examines the history of PEPFAR, the program’s sustainability, its use of public-private partnerships, and the potential impact of the closure earlier this month of the Global Health Initiative (GHI) office. Noting that next year marks the 10-year anniversary of PEPFAR, Devex concludes, “The Obama administration’s apparent about-face on components of GHI is but one reminder that in Washington — especially as administrations come and go — ideas, initiatives, and funding often fade away all too quickly. The U.S. foreign aid industry is no exception. If PEPFAR can continue its commitment to innovation and partnership, however, visitors to the U.S. capital this week [for the International AIDS Conference] can still be hopeful over America’s leadership role in the fight against HIV/AIDS” (Troilo/Piccio, 7/23).
“High levels of unmet need for contraception around the world have a very negative impact on women’s and children’s health and survival as well as on the prosperity of communities and nations,” Rep. Carolyn Maloney (D-N.Y.) writes in the Huffington Post’s “Global Motherhood” blog. “If these women had access to dependable voluntary contraception, unintended pregnancies would fall by more than 70 percent, 100,000 fewer women would die in childbirth, and nearly 600,000 fewer newborns would die each year,” she continues, adding, “If every woman had the option to leave a two-year gap between a birth and a subsequent pregnancy, deaths of children under five would fall by 13 percent.”
“Voluntary family planning services will reach an additional 120 million women and girls in the world’s poorest countries by 2020 thanks to a new set of commitments announced [at the London Summit on Family Planning on Wednesday] by more than 150 leaders from donor and developing countries, international agencies, civil society, foundations and the private sector,” a Bill & Melinda Gates Foundation press release reports (7/11). Donors “pledged $2.6 billion over the next eight years at [the summit], in what was described as a breakthrough for the world’s poorest women and girls,” the Guardian writes, adding, “More than 20 developing countries made commitments to boost spending on family planning and to strengthen women’s rights to ease their access to contraception” (Tran, 7/11). Speaking at the summit, Melinda Gates, co-chair of the Gates Foundation, announced the foundation “will spend more than $1 billion over the next eight years to increase access to contraceptives in the developing world and research new methods of birth control” and “outlined several of the initiatives [the foundation] will focus on in the coming years, including efforts to bring down the cost of birth control so that it will be within reach of the world’s poorest women,” the Seattle Times notes (Doughton, 7/11).
“The world’s first vaccine against dengue fever, being developed by French drugmaker Sanofi SA, protected against three of the virus’s four strains in a keenly awaited clinical trial in Thailand,” the company announced on Wednesday, Reuters reports (Hirschler/Regan, 7/25). “The vaccine actually generated antibody responses against all four strains of the virus, but for some reason, one strain was still able to infect children who received the vaccine, the company said, and scientists are now trying to figure out why,” the Los Angeles Times’ “Science Now” blog reports, adding, “Meanwhile, a much larger trial involving 31,000 adults and children is now under way in 10 countries in Asia and Latin America” (Maugh, 7/26). Reuters notes, “Other drug companies are also working on dengue vaccines but Sanofi’s product is several years ahead” (7/25).
Trade Agreements Could Harm Access To Antiretroviral Drugs In Asia, Pacific, Experts And Activists Warn
“Pressure on developing countries to adopt clauses affecting intellectual property rights could limit access to generic antiretroviral (ARV) drugs in Asia and the Pacific, experts and activists warn,” PlusNews reports. According to Steven Kraus, director of the UNAIDS program in Asia and the Pacific region, only about one-third of the people in need of treatment in the region receive it, and the long-term sustainability of even that proportion will be challenging in the current economic climate, the news service notes. Kraus said World Trade Organization (WTO) member states should take advantage of flexibilities under the Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement to manufacture and procure generic versions of medications “to ensure sustainability and the significant scale-up of HIV services to reach people most in need,” PlusNews continues.
“Secretary of State Hillary Rodham Clinton [on Thursday] hosted over 200 representatives from business, non-governmental organizations, and civil society groups to celebrate the power of collaboration,” Melanne Verveer, ambassador-at-large for global women’s issues, and Kris Balderston, the special representative for global partnerships, write in the State Department’s “DipNote” blog. “We…
“GlaxoSmithKline’s HIV/AIDS drugs business is to share intellectual property rights on children’s medicine in a patent pool designed to make treatments more widely available in poor countries,” Reuters reports. “ViiV Healthcare, majority-owned by GSK, is the second research-based pharmaceutical business to sign up to the new Medicines Patent Pool, following a lead set in…
Researchers Call For Increased Regulation Of Food, Drink Companies For Improvement Of Global Public Health
“Multinational food, drink and alcohol companies are using strategies similar to those employed by the tobacco industry to undermine public health policies, health experts said on Tuesday,” Reuters reports. In a study published in the Lancet, “[t]he researchers said that through the aggressive marketing of ultra-processed food and drink, multinational companies were now major…
“Not only is [Africa's] economic growth grabbing attention in boardrooms but the shifting nature of its disease burden is luring Big Pharma, as new opportunities open up for treating chronic diseases afflicting the middle classes, rather than just fire-fighting infection,” Reuters reports. According to data from IMS, a global health informatics and…